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A B S T R A C T
Burkholderia pseudomallei is a Gram-negative bacillus and the causative agent of melioidosis, a serious
infection associated with high mortality rate in humans. It can be naturally found as an environmental
saprophyte in soil or stagnant water, and rice paddies that predominate in regions of endemicity such as
Northeast Thailand. B. pseudomallei is a Biosafety Level 3 organism due to risks of aerosolization and
severe disease and is now included in formal emergency preparedness plans and guidelines issued by
various authorities in the United States and Europe. Here, we report the ﬁrst case of imported melioidosis
in Portugal. B. pseudomallei was isolated from the patient’s blood as well as from a left gluteal abscess
pus. The isolate strain showed the unusual resistance proﬁle to ﬁrst-line eradication therapy
trimethroprim/sulfamethoxazole. Whole genome sequencing revealed its similarity with isolates from
Southeast Asia, suggesting the Thai origin of this Portuguese isolate, which is in agreement with a recent
patient’s travel to Thailand.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Burkholderia pseudomallei is a Gram-negative bacillus that can
be naturally found as an environmental saprophyte in soil or
stagnant water [1]. It has been classiﬁed as a biothreat agent due to
risks of aerosolization, low infectious dose and high mortality rate
even with antimicrobial therapy [2,3].
B. pseudomallei is the etiologic agent of melioidosis, a serious
infection acquired by ingestion, inhalation or inoculation [4], and is
characterized by a wide range of clinical manifestations, including
pneumonia and sepsis [3]. According to the recently published [5]
estimated burden of melioidosis in 2015, the population at risk, as
well as the number of melioidosis cases and deaths are specially
relevant in South Asia, East Asia, Paciﬁc and Sub-Saharan Africa but
are also important in Latina American, Caribbean, Middle East and
North Africa. In fact in 2015 it is estimated at 1525 million people
are at risk to acquired melioidosis in South Asia. Of note, Florida in* Corresponding author. Tel.: +351 217519207.
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4.0/).the USA has been predicted to be environmental suitable for B.
pseudomallei persistence [5]. To date, no human case or isolation
of B. pseudomallei have been described in Portugal. Here, we report
the ﬁrst case of imported melioidosis in Portugal and the
characterization of the isolated strain.
Case report
In January 2011, a 62-year-old female patient was admitted to
the Hospital da Luz, Lisbon, Portugal, complaining of lower back
pain and a left lumbar mass for two months with subsequent
development of skin lesions and bilateral knee arthritis for two
weeks that worsened over four days, with night sweats episodes
without quantiﬁed fever. The patient had traveled to Thailand on
October 2010, during a heavy rain period. One month after arriving
home, the patient developed a left sciatic pain resistant to
analgesic therapy with a normal lumbar spine CT scan. Three
weeks before admission to Hospital da Luz, the patient noticed a
left lumbar mass and pustular lesion in the chin. One week later,
the patient went to a dermatology consultation, after noticing
ulcerated lesions on the outer side of the right arm and leg, and was
treated with amoxicillin/clavulanic acid and mupirocin for ﬁvee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
A. Pelerito et al. / IDCases 3 (2016) 10–11 11days, with partial resolution of the ulcerated lesions. Four days
before admission, the patient started feeling pain in both knee and
ankle joints, with edema and inﬂammatory signs. With continuing
complaints of left sciatic pain and left lumbar palpable mass, the
patient went to the hospital Emergency Service (in Hospital Luz) in
January 2011. On examination the patient had a left palpable
lumbar mass with 15 cm in greater diameter, arthritis of both
knees and two skin lesions on the right leg suggestive of erythema
nodosum.
Laboratory results showed a mild anemia and elevated
inﬂammatory parameters. Abdominopelvic CT scan showed a left
gluteal abscess (14  11 cm) with left ilium bone osteomyelitis
and a smaller contralateral gluteal abscess (5 cm). B. pseudomallei
was isolated from the patient’s blood as well as from the left gluteal
abscess. Identiﬁcation was made in Vitek 2 system (bioMe´rieux)
and species identity was subsequently conﬁrmed by a probe-based
real time PCR assay [6]. The patient was treated with intravenous
meropenem for 14 days, as recommended for treatment of patients
with complications during the acute phase [7], and regression of
the knee and ankle arthritis and skin lesions.
Considering the ﬁnding of resistance of the patient’s B.
pseudomallei strain (here designated as PtBps01) to the ﬁrst-line
eradication-phase therapy trimethroprim/sulfamethoxazole
(SXT), which is infrequently described [8–10], the patient was
discharged with the recommended [7] alternate oral antimicrobial
therapy with amoxicillin/clavulanic acid. Right gluteal abscess was
drained after two months of treatment and eradication therapy
was maintained for a total period of seven months, until full
resolution of the infectious process.
Genome sequencing
To perform the full genome characterization, the strain PtBps01
was subject to whole genome sequencing on a MiSeq Ilumina
platform (Illumina Inc., San Diego, CA, USA), and comparative
genomics against fully-sequenced B. pseudomallei strains available
in GenBank representative of several genome groups was
performed. Globally, the draft genome of PtBps01 harbors
7,117,230 bp with an average GC-content of 68.2%. Both core-
and pan-genome phylogenetic analyses grouped PtBps01 with
isolates from Southeast Asia, suggesting the Thai origin of this
Portuguese isolate. It appears to be most genetic relatedness to the
previously characterized Thai 1106a isolate, exhibiting >99% of
similarity in the core genome. PtBps01 accessory genome revealed
two putative intact prophages of 40.7Kb (%GC 64.6) and 25.1Kb
(%GC 66.0), both comprising 30 predicted CDSs revealing
homology with other Burkholderia phage sequences. No putative
plasmids were found in PtBps01.
The putative genetic basis for the observed unusual STX
resistance was also investigated, in particular those involving the
BpeEF-OprC efﬂux pump as it was already shown to confer
resistance to STX [11]. However, only three synonymous changes
(one in bpeE at 1014 bp and two in bpeF at 120 bp and 153 bp) in
PtBs01 isolate were found, suggesting that antimicrobial resistance
is governed by unidentiﬁed regulatory mechanism(s).Full-genome sequence was also used to extract loci sequences
for MLST analysis, revealing the allelic proﬁle 1-4-2-3-8-4-3, which
corresponds to sequence type (ST) 376. Based on public B.
pseudomallei MLST databases, no European isolate reported so
far displayed such ST proﬁle. The ST376 seems to be restricted to
Southeast Asia, as it was previously observed in water samples
collected in the 1960s in Thailand [12], as well as in human isolates
obtained in 2012 from a Laotian melioidosis patient with
suppurative parotitis and two Malay patients with bacteremia.
Conclusion
Altogether, the travel history of the Portuguese infected woman
and the genetic data of the isolated strain clearly indicate that this
ﬁrst Portuguese case of melioidosis is an importation from
Thailand. Considering that the signs of melioidosis are nonspeciﬁc
(resembling tuberculosis), this case reinforces the need for an
appropriate screening for the disease etiology in people traveling
from endemic areas.
Nucleotide sequence accession numbers. The complete
genome sequence of B. pseudomallei strain (PtBps01) has been
assigned the GenBank accession no. JNUQ00000000.
Consent section
Written informed consent was obtained from the patient for
publication of this case report. A copy of the written consent is
available for review by the Editor-in-Chief of this journal on
request.
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